Propanc Biopharma (PPCB) Stock Price, News & Analysis

Company Overview

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth. Propanc has conducted toxicology studies and in vitro assessments to establish safety profiles and enzyme stability, and it continues to advance its candidates through formulation optimization and manufacturing scale-up. In parallel, Propanc explores potential combination regimens with established oncology drugs to support future clinical trial designs.

Headquartered in Perth, Western Australia, with additional research collaborations in North America, Propanc Biopharma serves a global oncology community through its development partnerships and licensing discussions. The company is governed by a board and executive team with experience in biotechnology, protein engineering and clinical development, and it aims to position its enzyme-based platform as a complementary approach to existing cancer therapies.

Key Stats

• Today's Range: $2.10 to $2.50
• 50-Day Range: $1.73 to $10.40
• 52-Week Range: $1.25 to $145.46
• Volume: 1.09 million shs
• Average Volume: 848,031 shs
• Market Capitalization: $25.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PPCB Stock Analysis - Frequently Asked Questions

How have PPCB shares performed this year?

Propanc Biopharma's stock was trading at $0.0002 at the beginning of the year. Since then, PPCB stock has increased by 1,109,900.0% and is now trading at $2.22.

How were Propanc Biopharma's earnings last quarter?

Propanc Biopharma Inc (OTCMKTS:PPCB) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($12.50) EPS for the quarter.

When did Propanc Biopharma's stock split?

Propanc Biopharma's stock reverse split on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

When does the company's quiet period expire?

Propanc Biopharma's quiet period expires on Wednesday, September 24th. Propanc Biopharma had issued 1,000,000 shares in its initial public offering on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Propanc Biopharma?

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 9/14/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PPCB
• CIK: 1517681
• Web: www.propanc.com
• Phone: (139) 882-0780
• Fax: 61 03 9882 9969
• Employees: 1
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,652.66%
• Return on Assets: -971.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.24
• Quick Ratio: 2.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($493.34) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 11,612,000
• Free Float: 19,000
• Market Cap: $25.78 million
• Optionable: Not Optionable
• Beta: 2.66